Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication\n\n\n\n TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee, Unbuzzd Wellness Inc. (\"\n \n Unbuzzd\n \n \"), the company behind unbuzzd\n \n TM\n \n — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms — as part of its Reg D 506 (c) offering and up to $5 million raise, will host an Investor Webinar on Thursday, October 30, 2025 at 4:15 pm EST (1:15 pm PST). The shareholders of Quantum BioPharma will not be diluted by this offering.\n \n\n During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius, will discuss the current investment opportunity for its scientifically backed beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. Investors will also learn about the Company leadership and their path to scale distribution and retail sales. A question-and-answer session will follow the presentation.\n \n\n\n Unbuzzd Investor Webinar\n \n\n\n Date: Thursday, October 30, 2025\n \n\n Time: 4:15 PM EST (1:15 PM PST)\n \n\n\n\n Click Here to Register for the Webinar\n \n\n\n\n CEO of Unbuzzd John Duffy stated, “We invite potential investors to discuss our Regulation D 506(c) offering, targeting US$5.0 million to expand unbuzzd direct-to-consumer, distributor, and retail channel availability and work toward a possible IPO. Unbuzzd has the potential to be one of the most impactful new products of 2026 due to the meaningful innovation, functionality, relevance, and backing by clinical research. The brand has responded directly to emerging needs by connecting with consumers’ lifestyles and values.”\n \n\...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B